Brief Communication | Published:

Bariatric Surgery

The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery

Abstract

Neurotensin is a peptide with effects on appetite and intestinal lipid absorption. Experimental data suggest a role in glucose homeostasis, while human data is missing. Here, 20 morbidly obese subjects either underwent biliopancreatic diversion with duodenal switch (BPD), or Roux-en-Y gastric bypass (RYGB) in a randomized fashion. Before and 1 year after surgery, anthropometric data, body composition, clinical biochemistry, insulin sensitivity by means of euglycemic hyperinsulinemic clamps (HEC) and fasting plasma proneurotensin 1–117 were analyzed. Plasma proneurotensin increased significantly more 1 year after BDP than RYGB (P = 0.028), while weight loss was comparable. After metabolic surgery, proneurotensin correlated positively with insulin sensitivity (M-value) (r = 0.55, P < 0.001), while an inverse relationship with fasting glucose, HOMA-IR and HbA1c was observed (P < 0.05 for all components). After adjustment for age and gender, proneurotensin and BMI remained independently related with delta of M-value (β = 0.46 and β = 0.51, P < 0.05, resp.). From these data we conclude that proneurotensin positively correlates with insulin sensitivity uniquely after weight loss induced by metabolic surgery in humans. BDP leads to a stronger increase in the anorexigenic peptide compared to RYGB.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

These authors contributed equally: Christian von Loeffelholz, Lidia Castagneto Gissey.

References

  1. 1.

    Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964–73.

  2. 2.

    Raffaelli M, Iaconelli A, Nanni G, Guidone C, Callari C, Fernandez Real JM, et al. Effects of biliopancreatic diversion on diurnal leptin, insulin and free fatty acid levels. Br J Surg. 2015;102:682–90.

  3. 3.

    Armstrong MJ, Parker MC, Ferris CF, Leeman SE. Neurotensin stimulates [3H]oleic acid translocation across rat small intestine. Am J Physiol. 1986;251(6 Pt 1):G823–29.

  4. 4.

    Li J, Song J, Zaytseva YY, Liu Y, Rychahou P, Jiang K, et al. An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature. 2016;533:411–5.

  5. 5.

    Melander O, Maisel AS, Almgren P, Manjer J, Belting M, Hedblad B, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012;308:1469–75.

  6. 6.

    Ratner C, Skov LJ, Raida Z, Bächler T, Bellmann-Sickert K, Le Foll C, et al. Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery. Endocrinology. 2016;157:3482–92.

  7. 7.

    Holdstock C, Zethelius B, Sundbom M, Karlsson FA, Edén Engström B. Postprandial changes in gut regulatory peptides in gastric bypass patients. Int J Obes (Lond). 2008;32:1640–6.

  8. 8.

    Christ-Crain M, Stoeckli R, Ernst A, Morgenthaler NG, Bilz S, Korbonits M, Struck J, Bergmann A, Müller B, Keller U. Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients. J Clin Endocrinol Metab. 2006;91:3544–7.

  9. 9.

    Ernst A, Hellmich S, Bergmann A. Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation. Peptides. 2006;27:1787–93.

  10. 10.

    Januzzi JL Jr, Lyass A, Liu Y, Gaggin H, Trebnick A, Maisel AS, et al. Circulating proneurotensin concentrations and cardiovascular disease events in the community: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2016;36:1692–7.

  11. 11.

    Tewari N, Awad S, Macdonald IA, Lobo DN. Obesity-related insulin resistance: implications for the surgical patient. Int J Obes (Lond). 2015;39:1575–88.

  12. 12.

    Basso N, Soricelli E, Castagneto-Gissey L, Casella G, Albanese D, Fava F, et al. Insulin resistance, microbiota and fat distribution changes by a new model of vertical sleeve gastrectomy in obese rats. Diabetes. 2016;65:2990–3001.

  13. 13.

    Hanefeld M, Pistrosch F, Bornstein SR, Birkenfeld AL. The metabolic vascular syndrome - guide to an individualized treatment. Rev Endocr Metab Disord. 2016;17:5–17.

  14. 14.

    Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2016;108:16381–5.

  15. 15.

    Shigiyama F, Kumashiro N, Furukawa Y, Funayama T, Takeno K, Wakui N, et al. Characteristics of hepatic insulin-sensitive nonalcoholic fatty liver disease. Hepatol Commun. 2017;1:634–47.

Download references

Acknowledgements

We thank Julia Paditz and Stephan Friebe for excellent technical assistance. This work was funded by grant from the German Research Foundation (DFG) to ALB, GM, AK, SRB (IRTG 2251).

Author information

Conflict of interest

JS is employed by sphingotec GmbH, a company having patent rights in the proneurotensin assay and commercializing it. AB is CEO of sphingotec GmbH and holds shares in this company. The remaining authors declare that they have no conflict of interest.

Correspondence to Christian von Loeffelholz or Andreas L. Birkenfeld.

Electronic supplementary material

  1. Supplental Figure 1 and 2

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1